08/09/2026
Parkinson’s Disease is a progressive neurological disorder, and regenerative medicine continues to be an area of active research.
Umbilical cord-derived mesenchymal stem cells (MSCs)—the type of stem cells used at R3 Stem Cell—have been studied for their potential role in neuroprotection, reducing inflammation, and supporting neurological function.
Research in both animal models and clinical studies has shown promising findings for Parkinson’s patients. While stem cell therapy is not a cure, ongoing research continues to explore its potential as a regenerative approach.
A free consultation with R3 Stem Cell can help you understand your condition, your goals, and what regenerative therapy options may be available.
Disclaimer:
Stem cell therapy is considered experimental and is regulated by the U.S. Food and Drug Administration (FDA), but it is not FDA-approved. R3 Stem Cell does not offer stem cell therapy as a cure for any medical condition. No statements made on this page have been evaluated or approved by the FDA. This page does not provide medical advice. All content is for informational purposes only and is not a substitute for professional medical consultation, diagnosis, or treatment. Reliance on any information provided by R3 Stem Cell, its employees, others appearing on this page at the invitation of R3 Stem Cell, or other visitors to the page is solely at your own risk. R3 Stem Cell does not recommend or endorse any specific tests, products, procedures, opinions, or other information that may be mentioned on this website. R3 Stem Cell is not responsible for the outcome of your procedure. The FDA considers stem cell therapy experimental at this point.